Edasalonexent

DB15010InvestigationalSmall molecule

Edasalonexent is under investigation in clinical trial NCT01511900 (A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes).

Chemical structure of Edasalonexent
Formula / weight
C31H42N2O3 · 490.688 g/mol (avg)
Code names
CAT 1004

Resolves to

Compound
UNIIAF3Z6434KSCAS1204317-86-1ChEMBLCHEMBL3786673
Structure
InChIKeyJQLBBYLGWHUHRW-KUBAVDMBSA-NSMILESCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)C1=C(O)C=CC=C1
Targets
Q04864RELQ01201RELBQ04206RELAQ00653NFKB2P19838NFKB1

What you can answer from here — as of April 23, 2025

5Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
7Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Edasalonexent, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In